MCL-1 (myosin light chains-1) in differential diagnosis of dyspnea

Abstract

Myosin light chains-1 (MLC-1) have been recently associated with the markers of heart function (NYHA, LVEF, NT-proBNP). Verification of the relationship between markers of heart function (New York Heart Association classification (NYHA), left ventricle ejection fraction determination (LVEF), N terminal prohormone of natriuretic peptide B type BNP (NT-proBNP) and concentrations of myosin light chains-1 (MLC-1) was assesed. Patients examined for dyspnea without signs of acute coronary syndrome. All patients underwent echocardiography (calculation of left ventricle ejection fraction-LVEF) and in the serum of all subjects NT-proBNP (ELEIA) and MLC-1 (ELISA) were determined. In the 38 patients (21 men, 17 women), mean age of 58 years (±12 years as 1 SD), a significant negative correlation was found between NT-proBNP and LVEF (r =-0.47; p = 0.02, Spearman). The median levels of NT pro-BNP were closely associated with NYHA classification (type II-584 ng/l, type III-2792 ng/l, type IV-6400 ng/l; p < 0.05). Individuals with clinical NYHA IV differed significantly in median MLC-1 concentrations from persons with clinical NYHA classification II and III (type II-5.7 ng/l, type III-8.9 ng/l, type IV-17 ng/l; p <0.05). A significant negative correlation between MLC-1 and LVEF (-0.35; p <0.03) and significant positive correlations between MLC-1 and NT-proBNP (-0.42; p <0.012) were found. In conclusion MLC-1 cannot be used as a diagnostic marker in differential diagnosis of dyspnea.

Trastuzumab Alters the Expression of Genes Essential for Cardiac Function and Induces Ultrastructural Changes of Cardiomyocytes in Mice

“…Cardiac myosin light chain-1 (cMLC1) is a part of the myosin complex with an important role in cardiac muscle contraction. Impaired integrity of damaged or injured cardiomyocytes leads to release of cMLC1 from the myocardium into circulation [ 15 - 17 ]. It has not been reported if the release of cMLC1 from the myocardium into circulation is clinically related to trastuzumab-induced cardiotoxicity.…”

Biomarkers for Heart Failure

“…It is believed to be released into the blood via myofibril degeneration. Elevated levels of this circulating protein have been correlated with future acute deterioration, where significantly higher levels of MLC‐1 were associated with advanced HF 16,23 . Additionally in HF patients, concentrations of MLC‐1 have been correlated with levels of BNP 24 .…”

An Initial Evaluation of Human Plasma cMLC-1: A Potential Protein Biomarker for Trastuzumab-Induced Cardiotoxicity, Breast Cancer Screening and Progression

“…Cardiac myosin light chain-1 (cMLC-1, also known as myosin essential light chain (ELC)), is encoded by the MYL3 gene and is a part of the myosin complex that plays an important role in cardiac muscle contraction ( 11 , 12 ). Impaired integrity of damaged or injured cardiomyocytes leads to release of cMLC-1 from the myocardium into circulation ( 13 – 15 ). Past studies have shown that circulating cMLC-1 protein was elevated in patients a few hours after acute myocardial infarction, and peaked on days 2 to 4 post infarction ( 16 , 17 ).…”